Skip to main content
editorial
. 2017 May 10;8(5):820–822. doi: 10.1039/c7md90012k

Fig. 2. Chemical structure of osimertinib with in vivo xenograft activity and in the sensitising (PC-9, left) and T790M resistant models (H1975, right).3 Figure adapted from Cross et al. (2014) Cancer Discovery, 4, 1046–1061.

Fig. 2